Yantai Dongcheng Pharmaceutical Group Overview
- Year Founded
-
1998
- Status
-
Public
- Employees
-
2,583
- Stock Symbol
-
002675
- Investments
-
14
- Share Price
-
$1.78
- (As of Friday Closing)
Yantai Dongcheng Pharmaceutical Group General Information
Description
Yantai Dongcheng Biochemicals Co Ltd is a biochemical analytical profile index (API) manufacturers in China. In addition, the company also focuses on the development of finished preparation which covers the therapeutic area of cardiovascular, oncology, orthopedics, and anti-infection. Its product offering includes heparin sodium, chondroitin sulfate, marine collagen, hyaluronic acid, glucosamine, heparinoids, and cytochrome C. The company's API products have been exported to more than fifty countries and regions, including the United States of America, Germany, Austria, and Japan.
Contact Information
Website
www.dcb-group.comCorporate Office
- No.7 ChangBaiShan Road
- Yantai Development Zone
- Yantai, Shandong 264006
- China
Corporate Office
- No.7 ChangBaiShan Road
- Yantai Development Zone
- Yantai, Shandong 264006
- China
Yantai Dongcheng Pharmaceutical Group Stock Performance
As of 20-Nov-2026, Yantai Dongcheng Pharmaceutical Group’s stock price is $1.78. Its current market cap is $1.47B with 825M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.78 | $1.86 | $1.76 - $2.25 | $1.47B | 825M | 8.34M | $0.04 |
Yantai Dongcheng Pharmaceutical Group Financials Summary
As of 30-Sep-2026, Yantai Dongcheng Pharmaceutical Group has a trailing 12-month revenue of $382M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 1,790,499 | 1,736,967 | 1,497,779 | 2,217,713 |
| Revenue | 381,998 | 381,164 | 399,826 | 462,997 |
| EBITDA | 55,932 | 75,450 | 66,199 | 72,944 |
| Net Income | 30,482 | 27,203 | 25,619 | 29,645 |
| Total Assets | 1,357,281 | 1,318,302 | 1,182,816 | 1,140,191 |
| Total Debt | 186,535 | 107,993 | 117,616 | 105,895 |
Yantai Dongcheng Pharmaceutical Group Patents
Yantai Dongcheng Pharmaceutical Group Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026194083-A1 | Escherichia coli for high-yield production of fructosylated chondroitin, and production method for escherichia coli | Pending | 18-Mar-2025 | ||
| US-20260286412-A1 | High-yield fructosylated chondroitin-producing escherichia coli and its application thereof | Pending | 18-Mar-2025 | ||
| WO-2026194076-A1 | Preparation method for chondroitin sulfate sodium and use thereof | Pending | 18-Mar-2025 | ||
| US-20260286014-A1 | Preparation method for sodium chondroitin sulfate and use thereof | Pending | 18-Mar-2025 | ||
| WO-2025157248-A1 | Fucosylated chondroitin sulfate oligosaccharide derivative and use thereof | Pending | 26-Jan-2024 |
Yantai Dongcheng Pharmaceutical Group Signals
Yantai Dongcheng Pharmaceutical Group Investments & Acquisitions (14)
Yantai Dongcheng Pharmaceutical Group’s most recent deal was a Later Stage VC with Lannacheng Biotech for . The deal was made on 18-Jul-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Lannacheng Biotech | 18-Jul-2025 | Later Stage VC | Drug Discovery | ||
| Andico Pharmaceutical Group | 17-May-2025 | Merger/Acquisition | Diagnostic Equipment | ||
| Lannacheng Biotech | 14-Feb-2025 | Later Stage VC | Drug Discovery | ||
| Rongcheng Medical (Rights for 99mTc-GSA Injection and Cold Medicine Box) | 21-Feb-2024 | Corporate Asset Purchase | Buildings and Property | ||
| Lannacheng Biotech | 23-Jun-2023 | Early Stage VC | Drug Discovery |
Yantai Dongcheng Pharmaceutical Group ESG
Risk Overview
Risk Rating
Updated March, 31, 2025
40.15 | Severe Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,271
Rank
Percentile
Pharmaceuticals
Industry
of 908
Rank
Percentile
Pharmaceuticals
Subindustry
of 406
Rank
Percentile
Yantai Dongcheng Pharmaceutical Group Affiliates
Subsidiaries (6)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Lannacheng Biotech | Yantai, China | 2021 | |
| Shanghai Yitai Pharmaceutical Technology | Shanghai, China | 2016 | |
| Mitro Biotech | Nanjing, China | 2012 | |
| Andico Pharmaceutical Group | Hong Kong, Hong Kong | 2009 | |
| Sino Siam Biotechnique | Lopburi, Thailand | 2005 |
Yantai Dongcheng Pharmaceutical Group FAQs
-
When was Yantai Dongcheng Pharmaceutical Group founded?
Yantai Dongcheng Pharmaceutical Group was founded in 1998.
-
Where is Yantai Dongcheng Pharmaceutical Group headquartered?
Yantai Dongcheng Pharmaceutical Group is headquartered in Yantai, China.
-
What is the size of Yantai Dongcheng Pharmaceutical Group?
Yantai Dongcheng Pharmaceutical Group has 2,583 total employees.
-
What industry is Yantai Dongcheng Pharmaceutical Group in?
Yantai Dongcheng Pharmaceutical Group’s primary industry is Pharmaceuticals.
-
Is Yantai Dongcheng Pharmaceutical Group a private or public company?
Yantai Dongcheng Pharmaceutical Group is a Public company.
-
What is Yantai Dongcheng Pharmaceutical Group’s stock symbol?
The ticker symbol for Yantai Dongcheng Pharmaceutical Group is 002675.
-
What is the current stock price of Yantai Dongcheng Pharmaceutical Group?
As of 20-Nov-2026 the stock price of Yantai Dongcheng Pharmaceutical Group is $1.78.
-
What is the current market cap of Yantai Dongcheng Pharmaceutical Group?
The current market capitalization of Yantai Dongcheng Pharmaceutical Group is $1.47B.
-
What is Yantai Dongcheng Pharmaceutical Group’s current revenue?
The trailing twelve month revenue for Yantai Dongcheng Pharmaceutical Group is $382M.
-
What is Yantai Dongcheng Pharmaceutical Group’s annual earnings per share (EPS)?
Yantai Dongcheng Pharmaceutical Group’s EPS for 12 months was $0.04.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process